Search

Your search keyword '"Chouquet A"' showing total 346 results
Start Over Author "Chouquet A"
346 results on '"Chouquet A"'

302. L'Atlantique [Música notada] : scène chorale

Author

Thomas, Ambroise 1811-1896, Chouquet, Gustave 1819-1886, Thomas, Ambroise 1811-1896, and Chouquet, Gustave 1819-1886

Abstract

A pie de p. 1: "Nota. Le nombre des voix composant le petit choeur devra être à peu près dans la proportion d'un huitième de la masse générale des exécutants", Información del área de título tomada de la cabecera, Petit choeur (T(2)B(2)) et grand choeur (T(2)B(2)), Fecha de publicación basada en el Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

303. Le Tyrol [Música notada] : scéne chorale

Author

Thomas, Ambroise 1811-1896, Chouquet, Gustave 1819-1886, Thomas, Ambroise 1811-1896, and Chouquet, Gustave 1819-1886

Abstract

Notación musical grabada por L. Parent, Coro a 4 voces (T(2)B(2)), Información del área de título tomada de la cabecera, Datos de publicación tomados de la cabecera, Fecha de publicación tomada de The New Grove Dictionary of Music and Musicians, Macmillan, 2002

304. Le temple de la paix [Música notada] : choeur à 4 voix d'hommes

Author

Thomas, Ambroise 1811-1896, Chouquet, Gustave 1819-1886, Thomas, Ambroise 1811-1896, and Chouquet, Gustave 1819-1886

Abstract

T(2)B(2), Información del área de título tomada de la cabecera, Fecha de publicación tomada del Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

305. Blonde aux doux yeux [Música notada] : aubade

Author

Weckerlin, Jean-Baptiste 1821-1910, Chouquet, Gustave 1819-1886, Weckerlin, Jean-Baptiste 1821-1910, and Chouquet, Gustave 1819-1886

Abstract

Portada litografiada firmada por A. Jorel, En la port., se anuncia otra edición: "Ténor ou soprano", En la port., propaganda de otras obras del autor publicadas por la editorial, Voz y piano, Fecha de publicación tomada del Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

307. Le Tyrol [Música notada] : scéne chorale

Author

Thomas, Ambroise 1811-1896, Chouquet, Gustave 1819-1886, Thomas, Ambroise 1811-1896, and Chouquet, Gustave 1819-1886

Abstract

Notación musical grabada por L. Parent, Coro a 4 voces (T(2)B(2)), Información del área de título tomada de la cabecera, Datos de publicación tomados de la cabecera, Fecha de publicación tomada de The New Grove Dictionary of Music and Musicians, Macmillan, 2002

308. L'Atlantique [Música notada] : scène chorale

Author

Thomas, Ambroise 1811-1896, Chouquet, Gustave 1819-1886, Thomas, Ambroise 1811-1896, and Chouquet, Gustave 1819-1886

Abstract

A pie de p. 1: "Nota. Le nombre des voix composant le petit choeur devra être à peu près dans la proportion d'un huitième de la masse générale des exécutants", Información del área de título tomada de la cabecera, Petit choeur (T(2)B(2)) et grand choeur (T(2)B(2)), Fecha de publicación basada en el Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

309. Le temple de la paix [Música notada] : choeur à 4 voix d'hommes

Author

Thomas, Ambroise 1811-1896, Chouquet, Gustave 1819-1886, Thomas, Ambroise 1811-1896, and Chouquet, Gustave 1819-1886

Abstract

T(2)B(2), Información del área de título tomada de la cabecera, Fecha de publicación tomada del Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

311. Blonde aux doux yeux [Música notada] : aubade

Author

Weckerlin, Jean-Baptiste 1821-1910, Chouquet, Gustave 1819-1886, Weckerlin, Jean-Baptiste 1821-1910, and Chouquet, Gustave 1819-1886

Abstract

Portada litografiada firmada por A. Jorel, En la port., se anuncia otra edición: "Ténor ou soprano", En la port., propaganda de otras obras del autor publicadas por la editorial, Voz y piano, Fecha de publicación tomada del Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

312. À Mignonne [Música notada]

Author

Massenet, Jules 1842-1912, Chouquet, Gustave 1819-1886, Massenet, Jules 1842-1912, and Chouquet, Gustave 1819-1886

Abstract

Portada litografiada, Notación musical grabada por E. Beauvois, Ded.: "À mon ami Georges Hartmann", Voz y piano, Fecha de publicación basada en el Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

313. Berceuse [Música notada]

Author

Massenet, Jules 1842-1912, Chouquet, Gustave 1819-1886, Massenet, Jules 1842-1912, and Chouquet, Gustave 1819-1886

Abstract

Portada litografiada, Notación musical grabada por E. Beauvois, Ded.: "À mon ami Georges Hartmann", Fecha de publicación basada en el Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

314. Déclaration [Música notada]

Author

Massenet, Jules 1842-1912, Chouquet, Gustave 1819-1886, Shelley, Percy Bysshe 1792-1822, Massenet, Jules 1842-1912, Chouquet, Gustave 1819-1886, and Shelley, Percy Bysshe 1792-1822

Abstract

Portada litografiada, Notación musical grabada por E. Beauvois, Ded.: "À mon ami Georges Hartmann", Voz y piano, Fecha de publicación basada en el Dictionnaire des éditeurs de musique français, volume II, de 1820 à 1914, 1988

315. Micro-injection moulding: surface treatment effects on part demoulding

Author

Dimov, S., Menz, W., Griffiths, C. A., Dimov, Stefan Simeonov, Brousseau, Emmanuel Bruno Jean Paul, Chouquet, C., Gavillet, J., Bigot, Samuel, Dimov, S., Menz, W., Griffiths, C. A., Dimov, Stefan Simeonov, Brousseau, Emmanuel Bruno Jean Paul, Chouquet, C., Gavillet, J., and Bigot, Samuel

317. Essai sur la composition chorale

Author

Meyerbeer, Giacomo (1791-1864). Compositeur, Kücken, Friedrich Wilhelm (1810-1882). Compositeur, Soubre, Etienne-Joseph (1813-1871). Compositeur, Limnander de Nieuwenhove, Armand (1814-1892). Compositeur, Thomas, Ambroise (1811-1896). Compositeur, Clapisson, Antoine-Louis (1808-1866). Compositeur, Kastner, Jean-Georges (1810-1867). Compositeur, Bazin, Francois (1816-1878). Compositeur, Rillé, Laurent de (1824-1915). Compositeur, Elwart, Antoine (1808-1877). Compositeur, Clapisson, Antoine-Louis (1808-1866). Auteur ou responsable intellectuel, Lyden, Émile Mignot de (1815-1894). Auteur ou responsable intellectuel, Rillé, Laurent de (1824-1915). Auteur ou responsable intellectuel, Elwart, Antoine (1808-1877). Auteur du texte, Deschamps, Émile (1791-1871). Auteur du texte, Ceuxerick, A.. Auteur du texte, Gensse, G.. Auteur du texte, Lyden, Émile Mignot de (1815-1894). Auteur du texte, Chouquet, Gustave (1819-1886). Auteur du texte, Flan, Alexandre (1827-1870). Auteur du texte, Vialon, Antoine (1814-1866). Auteur du texte, La Fontaine, Jean de (1621-1695). Auteur du texte, Villemin, E.. Auteur du texte, Meyerbeer, Giacomo (1791-1864). Compositeur, Kücken, Friedrich Wilhelm (1810-1882). Compositeur, Soubre, Etienne-Joseph (1813-1871). Compositeur, Limnander de Nieuwenhove, Armand (1814-1892). Compositeur, Thomas, Ambroise (1811-1896). Compositeur, Clapisson, Antoine-Louis (1808-1866). Compositeur, Kastner, Jean-Georges (1810-1867). Compositeur, Bazin, Francois (1816-1878). Compositeur, Rillé, Laurent de (1824-1915). Compositeur, Elwart, Antoine (1808-1877). Compositeur, Clapisson, Antoine-Louis (1808-1866). Auteur ou responsable intellectuel, Lyden, Émile Mignot de (1815-1894). Auteur ou responsable intellectuel, Rillé, Laurent de (1824-1915). Auteur ou responsable intellectuel, Elwart, Antoine (1808-1877). Auteur du texte, Deschamps, Émile (1791-1871). Auteur du texte, Ceuxerick, A.. Auteur du texte, Gensse, G.. Auteur du texte, Lyden, Émile Mignot de (1815-1894). Auteur du texte, Chouquet, Gustave (1819-1886). Auteur du texte, Flan, Alexandre (1827-1870). Auteur du texte, Vialon, Antoine (1814-1866). Auteur du texte, La Fontaine, Jean de (1621-1695). Auteur du texte, and Villemin, E.. Auteur du texte

Abstract

Comprend : Adieu aux jeunes mariés ; Dans la forêt ; Prière avant la bataille ; Les Contrebandiers ; Le Carnaval de Rome ; La Parole de Dieu ; Départ et retour ; Le Départ des apôtres ; Le Matin ; Le Loup et l'agneau ; Ruth et Booz (fragment), Appartient à l’ensemble documentaire : MethMusiq, Contient une table des matières, Avec mode texte

323. Les alluvions de Chelles

Author

Chouquet

Subjects
General Medicine
Abstract

Chouquet . Les alluvions de Chelles.. In: Bulletins de la Société d'anthropologie de Paris, III° Série. Tome 7 fascicule 3, 1884. pp. 464-465.

Published
1884
Full Text
View/download PDF

324. Développement et validation d’une méthode de dosage de gélules pédiatriques de lévofloxacine hémihydrate

Author

Rousseau, Julia, Le Meur, Lucie, Chouquet, Thibaut, Bordenave, Joëlle, and Benoit, Guy

Abstract

La lévofloxacine est indiquée dans la prise en charge de la tuberculose multirésistante chez l’enfant à la posologie de 15mg/kg/jour en une prise unique. En l’absence de spécialités adaptées à l’enfant, des gélules de lévofloxacine dosées entre 50 et 300mg sont réalisées au préparatoire. L’objectif de ce travail est de développer et de valider une méthode de dosage de ces préparations, afin de pouvoir réaliser en routine un essai de teneur.

Published
2017
Full Text
View/download PDF

328. Thriving life beneath: Biodiversity and functioning of macrobenthic communities within two human-shaped European estuaries.

Author

Lécuyer, Romain, Brind'Amour, Anik, Barillé, Anne-Laure, Chouquet, Bastien, and Le Bris, Hervé

Subjects
*ESTUARIES, *ORIGINALITY, *BIODIVERSITY, *ECOSYSTEMS
Abstract

[Display omitted] • The Loire and Seine estuaries have lost 28 % and 43 % of their surfaces over the last century. • Polyhaline mudflats featured higher production and more diverse macrobenthic communities. • Functional richness was significantly linked to macrobenthic production, suggesting more efficient resource utilization. • High functional originality and specialization highlighted potential vulnerabilities in the event of ecosystem changes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

329. The C-terminal polyproline-containing region of ELMO contributes to an increase in the life-time of the ELMO-DOCK complex

Author

Sévajol, Marion, Reiser, Jean-Baptiste, Chouquet, Anne, Pérard, Julien, Ayala, Isabel, Gans, Pierre, Kleman, Jean-Philippe, and Housset, Dominique

Subjects
*POLYPROLINE, *C-terminal binding proteins, *EUKARYOTIC cells, *CELL motility, *SURFACE plasmon resonance, *NUCLEAR magnetic resonance spectroscopy, *BIOCHEMISTRY
Abstract

Abstract: The eukaryotic Engulfment and Cell Motility (ELMO) proteins form an evolutionary conserved family of key regulators which play a central role in Rho-dependent biological processes such as engulfment and cell motility/migration. ELMO proteins interact with a subset of Downstream of Crk (DOCK) family members, a new type of guanine exchange factors (GEF) for Rac and cdc42 GTPases. The physiological function of DOCK is to facilitate actin remodeling, a process which occurs only in presence of ELMO. Several studies have determined that the last 200 C-terminal residues of ELMO1 and the first 180 N-terminal residues of DOCK180 are responsible for the ELMO-DOCK interaction. However, the precise role of the different domains and motifs identified in these regions has remained elusive. Divergent functional, biochemical and structural data have been reported regarding the contribution of the C-terminal end of ELMO, comprising its polyproline motif, and of the DOCK SH3 domain. In the present study, we have investigated the contribution of the C-terminal end of ELMO1 to the interaction between ELMO1 and the SH3 domain of DOCK180 using nuclear magnetic resonance spectroscopy and surface plasmon resonance. Our data presented here demonstrate the ability of the SH3 domain of DOCK180 to interact with ELMO1, regardless of the presence of the polyproline-containing C-terminal end. However, the presence of the polyproline region leads to a significant increase in the half-life of the ELMO1-DOCK180 complex, along with a moderate increase on the affinity. [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

331. Liver fibrosis and all‐cause mortality in chronic HCV‐infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER)

Author

Tangui, Barré, Clémence, Ramier, Vincent, Di Beo, Fabrice, Carrat, Hélène, Fontaine, Fabienne, Marcellin, Patrizia, Carrieri, Stanislas, Pol, Camelia, Protopopescu, Marie-Josée, Lafrance, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunité Innée - Innate Immunity, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), ANRS/AFEF Hepather study group: Delphine Bonnet, Virginie Sicart, François Bailly, Marjolaine Beaudoin, Dominique Giboz, Kerstin Hartig-Lavie, Marianne Maynard, Morane Cavellec, Marjorie Cheraud-Carpentier, François Raffi, Florian Vivrel, Jaouad Benhida, Jérôme Boursier, Paul Calès, Françoise Lunel, Frédéric Oberti, Nathalie Boyer, Audrey Gilibert, Nathalie Giuily, Giovanna Scoazec, Sandrine Fernandes, Sylvie Keser, Philippe Sultanik, Anaïs Vallet-Pichard, Juliette Foucher, Jean-Baptiste Hiriart, Aurore Mathias, Julien Vergniol, Chrystelle Ansaldi, Laëtitia Chouquet, Emilie De Luca, Valérie Oules, Rodolphe Anty, Eve Gelsi, Régine Truchi, Elena Luckina, Nadia Messaoudi, Joseph Moussali, Barbara De Dieuleveult, Damien Labarriere, Pascal Poter, Si Nafa Si Ahmed, Nathalie Ganne-Carrié, Véronique Grando-Lemaire, Pierre Nahon, Alan Peltier, Judith Ung, Mariette Gougeon, Anne Guillygomarch, Caroline Jezequel, Romain Moirand, Thomas F Baumert, Michel Dofföel, Catherine Mutter, Pauline Simo-Noumbissie, Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani-Nani, Marie-Albertine Bernard, Michael Bismuth, Ludovic Caillo, Stéphanie Faure, Georges-Philippe Pageaux, Marie P Ripault, Karl Barange, Christophe Bureau, Jean M Peron, Marie A Robic, Léa Tarallo, Marine Faure, Bruno Froissart, Marie-Noelle Hilleret, Vincent Leroy, Odile Goria, Victorien Grard, Hélène Montialoux, Muriel François, Christian Ouedraogo, Christelle Pauleau, Anne Varault, Tony Andreani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty, Teresa Antonini, Audrey Coilly, Jean-Charles D Vallée, Mariagrazia Tateo, Armand Abergel, Corinne Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti, Abdenour Babouri, Virginie Filipe, Camille Barrault, Laurent Costes, Hervé Hagège, Soraya Merbah, Paul Carrier, Maryline Debette-Gratien, Jérémie Jacques, Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet, Marc Bardou, Donya Da Costa Souhiel, Patrick Hillon, Marianne Latournerie, Yannick Bacq, Didier Barbereau, Charlotte Nicolas, Nisserine B Amara, Danièle Botta-Fridlund, Isabelle Portal, Moana Gelu-Simeon, Marie-Josée Lafrance, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), The cohort received financial support from the INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites), the French ANR (Agence Nationale de la Recherche), the French DGS (Direction Générale de la Santé), Merck Sharp and Dohme, Janssen-Cilag, Gilead, Abbvie, Bristol-Myers Squibb and Roche. FC reports grants from INSERM-ANRS, during the conduct of the study, and personal fees from Imaxio, outside the submitted work. MB reports grants and personal fees from AbbVie and Gilead, outside the submitted work, and personal fees from MSD, Janssen, Boehringher Ingelheim, Intercept and Bristol-Myers Squibb, outside the submitted work. SP has received consulting and lecturing fees from Bristol-Myers Squibb, Janssen, Gilead, Roche, MSD, MYR-Pharma, Shionogi, Biotest and Abbvie, as well as grants from Bristol-Myers Squibb, Gilead, Roche and MSD. HF reports personal fees and invitations for medical meetings from Gilead, AbbVie, Bristol-Myers Squibb, MSD and Janssen, outside the submitted work. Other authors declare no financial support., and Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Liver Cirrhosis, 0303 health sciences, medicine.medical_specialty, Hepatology, business.industry, Liver fibrosis, [SDV]Life Sciences [q-bio], Hepatitis C, Chronic, Antiviral Agents, Gastroenterology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Text mining, Internal medicine, Diabetes Mellitus, medicine, Humans, 030211 gastroenterology & hepatology, business, All cause mortality, ComputingMilieux_MISCELLANEOUS, Follow-Up Studies, 030304 developmental biology
Abstract

International audience; No abstract available

Published
2021
Full Text
View/download PDF

332. Effectiveness of direct‐acting antivirals for chronic hepatitis C treatment in migrant and non‐migrant populations in France

Author

Mélanie Simony, Stanislas Pol, Elisabeth Delarocque-Astagneau, Hélène Fontaine, Fabrice Carrat, Tchadine Djaogol, Maël Baudoin, Fabienne Marcellin, Patrizia Carrieri, Ventzislava Petrov-Sanchez, Marc Bourlière, Camelia Protopopescu, Céline Dorival, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunobiologie des Cellules Dendritiques, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Recherches fondamentales, cliniques et thérapeutiques sur les hépatites virales [Paris] (ANRS), ANRS France Recherche Nord & sud Sida-hiv hépatites, Hôpital Saint-Joseph [Marseille], Biostatistique, Biomathématique, Pharmacoépidémiologie et Maladies Infectieuses (B2PHI), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), The cohort received financial support from INSERM-ANRS (France Recherche Nord & Sud Sida-HIV Hépatites), the French ANR (Agence Nationale de la Recherche), the French DGS (Direction Générale de la Santé), Merck Sharp and Dohme, Janssen-Cilag, Gilead, Abbvie, Bristol-Myers Squibb and Roche., ANRS CO22 Hepather study group, ANRS-AFEF HEPATHER STUDY GROUP: Delphine Bonnet, Virginie Sicart (CHU Purpan, Toulouse, France), François Bailly, Marjolaine Beaudoin, Dominique Giboz, Kerstin Hartig-Lavie, Marianne Maynard(Hospices Civils de Lyon, Lyon, France), Morane Cavellec, Marjorie Cheraud-Carpentier, François Raffi, Florian Vivrel (Hôpital Hôtel-Dieu, Nantes, France), Jaouad Benhida, Jérôme Boursier, Paul Calès, Françoise Lunel, Frédéric Oberti (CHU Angers, Angers, France), Nathalie Boyer, Audrey Gilibert, Nathalie Giuily (Hôpital Beaujon, Clichy, France), Giovanna Scoazec (Hôpital Beaujon, Clichy, France and Hôpital Henri Mondor, Créteil, France), Sandrine Fernandes, Sylvie Keser, Philippe Sultanik, Anaïs Vallet-Pichard (Hôpital Cochin, Paris, France), Juliette Foucher, Jean-Baptiste Hiriart, Aurore Mathias, Julien Vergniol (Hôpital Haut-Lévêque, Pessac, Bordeaux, France), Chrystelle Ansaldi, Laëtitia Chouquet, Emilie De Luca, Valérie Oules (Hôpital Saint Joseph, Marseille, France), Rodolphe Anty, Eve Gelsi, Régine Truchi (CHU de Nice, Nice, France), Elena Luckina, Nadia Messaoudi, Joseph Moussali, (Groupe Hospitalier Pitié-Salpétrière, Paris, France), Barbara De Dieuleveult, Damien Labarriere, Pascal Poter, Si Nafa Si Ahmed (CHR La Source, Orléans, France), Nathalie Ganne-Carrié, Véronique Grando-Lemaire, Pierre Nahon, Alan Peltier, Judith Ung (Hôpital Jean Verdier, Bondy, France), Mariette Gougeon, Anne Guillygomarch, Caroline Jezequel (CHU Rennes, Rennes, France), Romain Moirand, Thomas F. Baumert, Michel Dofföel, Catherine Mutter, Pauline Simo-Noumbissie (Hôpitaux Universitaires de Strasbourg, Strasbourg, France), Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani-Nani (CHU de Nancy, Vandoeuvre-lès-Nancy, France), Marie-Albertine Bernard (CHU de Nancy, Vandoeuvre-lès-Nancy, France and Centre Hospitalier Régional, Metz, France), Michael Bismuth, Ludovic Caillo, Stéphanie Faure, Georges-Philippe Pageaux, Marie Pierre Ripault (Hôpital Saint Eloi, Montpellier, France), Karl Barange, Christophe Bureau, Jean Marie Peron, Marie Angèle Robic, Léa Tarallo (CHU Purpan, Toulouse, France), Marine Faure, Bruno Froissart, Marie-Noelle Hilleret, Vincent Leroy (CHU de Grenoble, Grenoble, France), Odile Goria, Victorien Grard, Hélène Montialoux (CHU Charles Nicolle, Rouen, France), Muriel François, Christian Ouedraogo, Christelle Pauleau, Anne Varault (Hôpital Henri Mondor, Créteil, France), Tony Andreani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty (Hôpital Saint-Antoine, Paris, France), Teresa Antonini, Audrey Coilly, Jean-Charles Duclos Vallée, Mariagrazia Tateo (Hôpital Paul Brousse, Villejuif, France), Armand Abergel, Corinne Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti (Hôpital Estaing, Clermont-Ferrand, France), Abdenour Babouri, Virginie Filipe (Centre Hospitalier Régional, Metz, France), Camille Barrault, Laurent Costes, Hervé Hagège, Soraya Merbah (Centre Hospitalier Intercommunal, Créteil, France), Paul Carrier, Maryline Debette-Gratien, Jérémie Jacques (CHU Limoges, Limoges, France), Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet (CHRU Claude Huriez, Lille, France), Marc Bardou, Donya Da Costa Souhiel, Patrick Hillon, Marianne Latournerie (Dijon University Hospital, Dijon, France), Yannick Bacq, Didier Barbereau, Charlotte Nicolas (CHU Trousseau, 37 044 Tours, France), Nisserine Ben Amara, Danièle Botta-Fridlund, Isabelle Portal (CHU Timone, Marseille, France), Moana Gelu-Simeon and Marie-Josée Lafrance (CHU de Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe)., Université Paris Descartes - Paris 5 (UPD5), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, [SDV]Life Sciences [q-bio], Hepacivirus, Antiviral Agents, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Central Asia, Chronic hepatitis, Interquartile range, medicine, Humans, Prospective Studies, Poisson regression, Prospective cohort study, Socioeconomic status, direct-acting antivirals, Aged, Transients and Migrants, Hepatology, business.industry, virus diseases, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, 3. Good health, migrant, Cross-Sectional Studies, vulnerable population, 030220 oncology & carcinogenesis, symbols, Population study, population characteristics, 030211 gastroenterology & hepatology, France, hepatitis C, sustained virological response, business, Social vulnerability, Demography
Abstract

International audience; Despite universal health coverage in France, migrants face specific socioeconomic barriers that increase the likelihood of a suboptimal cascade of care for chronic hepatitis C virus (HCV) infection and impaired treatment effectiveness in this sub-population. We selected data collected from 2012 to 2018 from the ANRS CO22 HEPATHER prospective cohort study for chronic HCV participants with available data on treatment failure (defined as the presence of a detectable HCV-RNA load 12 weeks after their first DAA treatment ended). We performed multivariable Poisson regression models to test whether treatment failure rates differed significantly between HCV-infected migrants and non-migrants receiving DAA in France (cross-sectional analysis), while taking into account the former's world region of birth and other potential social vulnerability factors. Among the study population's 7,879 patients, 5,829 (74%) were non-migrants and 2,050 (26%) migrants. Median [interquartile range] age was 57 [51-65] years, 4433 (56%) were men and 369 (5%) of the entire study population had treatment failure. After multivariable adjustment, only migrants from Central Asia were at higher risk of treatment failure than non-migrants (aIRR = 2.83; 95% CI [1.72, 4.65]). Results from this large-scale study performed in France suggest a higher risk of DAA treatment failure in migrants from Central Asia than in non-migrants and confirm the overall low treatment failure rate in chronic HCV patients treated with DAA (whether migrants or not). Simplified models of care taking into account language and cultural barriers are needed to improve DAA effectiveness in migrants from Central Asia.

Published
2021
Full Text
View/download PDF

333. Les compétences de l’État du port en matière de protection des ressources halieutiques

Author

Sophie GAMBARDELLA, Droits International, Comparé et Européen / Centre d'études et de recherches internationales et communautaires (CERIC) (DICE / CERIC), Droits International, Comparé et Européen (DICE), Centre National de la Recherche Scientifique (CNRS)-Université de Toulon (UTLN)-Université de Pau et des Pays de l'Adour (UPPA)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Université de Toulon (UTLN)-Université de Pau et des Pays de l'Adour (UPPA)-Aix Marseille Université (AMU), Marine CHOUQUET et Julia MOTTE-BAUMVOL, and Aix Marseille Université (AMU)-Université de Pau et des Pays de l'Adour (UPPA)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Université de Pau et des Pays de l'Adour (UPPA)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SHS.DROIT]Humanities and Social Sciences/Law, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021

334. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort)

Author

Barré, Tangui, Nishimwe, Marie Libérée, Protopopescu, Camelia, Marcellin, Fabienne, Carrat, Fabrice, Dorival, Céline, Delarocque-Astagneau, Elisabeth, Larrey, Dominique G., Bourlière, Marc, Petrov-Sanchez, Ventzislava, Simony, Mélanie, Pol, Stanislas, Fontaine, Hélène, Carrieri, Patrizia Maria, Pageaux, Georges Philippe, HAL UVSQ, Équipe, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Biostatistique, Biomathématique, Pharmacoépidémiologie et Maladies Infectieuses (B2PHI), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Merck Sharp and Dohme, MSD Agence Nationale de la Recherche, ANR AbbVie Bristol-Myers Squibb, BMS AbbVie Association Française pour l'Etude du Foie, AFEF Roche Gilead Sciences Shionogi Cilag MSD France, FC reports grants from INSERM-ANRS, during the conduct of the study, and personal fees from Imaxio, outside the submitted work. MB reports grants and personal fees from AbbVie and Gilead, outside the submitted work, and personal fees from MSD, Janssen, Boehringher Ingelheim, Intercept, and Bristol-Myers Squibb, outside the submitted work. SP has received consulting and lecturing fees from Bristol-Myers Squibb, Janssen, Gilead, Roche, MSD, MYR-Pharma, Shionogi, Biotest and Abbvie, as well as grants from Bristol-Myers Squibb, Gilead, Roche and MSD. HF reports personal fees and invitations for medical meetings from Gilead, AbbVie, Bristol-Myers Squibb, MSD, and Janssen, outside the submitted work. Other authors declare no financial support. The cohort received financial support from the INSERM-ANRS (France Recherche Nord & Sud Sida-HIV H?patites), the French ANR (Agence Nationale de la Recherche), the French DGS (Direction Générale de la Santé), Merck Sharp and Dohme, Janssen-Cilag, Gilead, Abbvie, Bristol-Myers Squibb, and Roche. Those funding sources had no role in the writing of the manuscript or the decision to submit it for publication. We thank the study participants and the participating clinicians at each site. We also thank the INSERM-ANRS for sponsoring, funding and conducting the ANRS CO22 Hepather cohort in collaboration with the French Association for the Study of the Liver (Association Fran?aise pour l'Etude du Foie: AFEF). Finally, our thanks to Jude Sweeney for the English revision and editing of our manuscript., On behalf of the ANRS/AFEF Hepather study group : Delphine Bonnet, Virginie Sicart (CHU Purpan, Toulouse, France), François Bailly, Marjolaine Beaudoin, Dominique Giboz, Kerstin Hartig‐Lavie, Marianne Maynard (Hospices Civils de Lyon, Lyon, France), Morane Cavellec, Marjorie Cheraud‐Carpentier, François Raffi, Florian Vivrel (Hôpital Hôtel‐Dieu, Nantes, France), Jaouad Benhida, Jérôme Boursier, Paul Calès, Françoise Lunel, Frédéric Oberti (CHU Angers, Angers, France), Nathalie Boyer, Audrey Gilibert, Nathalie Giuily (Hôpital Beaujon, Clichy, France), Giovanna Scoazec (Hôpital Beaujon, Clichy, France and Hôpital Henri Mondor, Créteil, France), Sandrine Fernandes, Sylvie Keser, Philippe Sultanik, Anaïs Vallet‐Pichard (Hôpital Cochin, Paris, France), Juliette Foucher, Jean‐Baptiste Hiriart, Aurore Mathias, Julien Vergniol (Hôpital Haut‐Lévêque, Pessac, Bordeaux, France), Chrystelle Ansaldi, Laëtitia Chouquet, Emilie De Luca, Valérie Oules (Hôpital Saint Joseph, Marseille, France), Rodolphe Anty, Eve Gelsi, Régine Truchi (CHU de Nice, Nice, France), Elena Luckina, Nadia Messaoudi, Joseph Moussali, (Groupe Hospitalier Pitié‐Salpétrière, Paris, France), Barbara De Dieuleveult, Damien Labarriere, Pascal Poter, Si Nafa Si Ahmed (CHR La Source, Orléans, France), Nathalie Ganne‐Carrié, Véronique Grando‐Lemaire, Pierre Nahon, Alan Peltier, Judith Ung (Hôpital Jean Verdier, Bondy, France), Mariette Gougeon, Anne Guillygomarch, Caroline Jezequel (CHU Rennes, Rennes, France), Romain Moirand, Thomas F. Baumert, Michel Dofföel, Catherine Mutter, Pauline Simo‐Noumbissie (Hôpitaux Universitaires de Strasbourg, Strasbourg, France), Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani‐Nani (CHU de Nancy, Vandoeuvre‐lès‐Nancy, France), Marie‐Albertine Bernard (CHU de Nancy, Vandoeuvre‐lès‐Nancy, France and Centre Hospitalier Régional, Metz, France), Michael Bismuth, Ludovic Caillo, Stéphanie Faure, Georges‐Philippe Pageaux, Marie Pierre Ripault (Hôpital Saint Eloi, Montpellier, France), Karl Barange, Christophe Bureau, Jean Marie Peron, Marie Angèle Robic, Léa Tarallo (CHU Purpan, Toulouse, France), Marine Faure, Bruno Froissart, Marie‐Noelle Hilleret, Vincent Leroy (CHU de Grenoble, Grenoble, France), Odile Goria, Victorien Grard, Hélène Montialoux (CHU Charles Nicolle, Rouen, France), Muriel François, Christian Ouedraogo, Christelle Pauleau, Anne Varault (Hôpital Henri Mondor, Créteil, France), Tony Andreani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty (Hôpital Saint‐Antoine, Paris, France), Teresa Antonini, Audrey Coilly, Jean‐Charles Duclos Vallée, Mariagrazia Tateo (Hôpital Paul Brousse, Villejuif, France), Armand Abergel, Corinne Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti (Hôpital Estaing, Clermont‐Ferrand, France), Abdenour Babouri, Virginie Filipe (Centre Hospitalier Régional, Metz, France), Camille Barrault, Laurent Costes, Hervé Hagège, Soraya Merbah (Centre Hospitalier Intercommunal, Créteil, France), Paul Carrier, Maryline Debette‐Gratien, Jérémie Jacques (CHU Limoges, Limoges, France), Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet (CHRU Claude Huriez, Lille, France), Marc Bardou, Donya Da Costa Souhiel, Patrick Hillon, Marianne Latournerie (Dijon University Hospital, Dijon, France), Yannick Bacq, Didier Barbereau, Charlotte Nicolas (CHU Trousseau, 37044 Tours, France), Nisserine Ben Amara, Danièle Botta‐Fridlund, Isabelle Portal (CHU Timone, Marseille, France), Moana Gelu‐Simeon, Marie‐Josée Lafrance (CHU de Pointe‐à‐Pitre, Pointe‐à‐Pitre, Guadeloupe)., Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Eloi, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
Liver Cirrhosis, cannabis, medicine.medical_specialty, Population, HIV Infections, 030209 endocrinology & metabolism, marijuana smoking, Lower risk, 03 medical and health sciences, 0302 clinical medicine, Insulin resistance, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Virology, Diabetes mellitus, Internal medicine, medicine, Humans, Risk factor, education, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, education.field_of_study, Hepatology, biology, business.industry, 1. No poverty, Hepatitis C, Hepatitis C, Chronic, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, biology.organism_classification, 3. Good health, chronic, Cross-Sectional Studies, Infectious Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Cohort, diabetes mellitus, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030211 gastroenterology & hepatology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cannabis, France, business
Abstract

International audience; Chronic hepatitis C virus (HCV) infection is a risk factor of insulin resistance, and HCV-infected patients are at a high risk of developing diabetes. In the general population, research has shown the potential benefit of cannabis use for the prevention of diabetes and related metabolic disorders. We aimed to test whether cannabis use is associated with a lower risk of diabetes in chronic HCV-infected patients. Chronic HCV-infected patients (n = 10 445) were selected from the French national, multicenter, observational ANRS CO22 Hepather cohort. Cross-sectional data collected at cohort enrollment were used to assess the association between patients’ clinical and behavioural characteristics and the risk of diabetes. Logistic regression model was performed with cannabis use as the main independent variable and a significance level set at 5%. A similar model stratified by the presence of advanced liver fibrosis (FIB-4 > 3.25) was also run. After multivariable adjustment, current (AOR [95%CI]: 0.49 [0.38-0.63]) and former (0.81 [0.67-0.98], P

Published
2020
Full Text
View/download PDF

336. Molecular dissection of the interaction of C1q with CD91.

Author

Bally, Isabelle, Gout, Evelyne, Wicker-Planquart, Catherine, Chouquet, Anne, Frachet, Philippe, Thielens, Nicole M., Kleman, Jean-Philippe, and Rossi, Véronique

Subjects
*LOW density lipoprotein receptor-related proteins, *COMPLEMENT activation, *MOLECULAR interactions, *APOPTOSIS, *HOMEOSTASIS, *IMMUNOLOGICAL tolerance
Published
2016
Full Text
View/download PDF

337. To click or not to click for short pulse-labeling of the bacterial cell wall.

Author

Baudoin M, Chouquet A, Nguyen M, Zapun A, Pérès B, Morlot C, Durmort C, and Wong YS

Abstract

A method of choice to study the spatio-temporal dynamics of bacterial cell growth and division is to analyze the localization of cell wall synthesis regions by fluorescence microscopy. For this, nascent cell wall biopolymers need to be labeled with fluorescent reporters, like fluorescent d-alanines (FDAs) that can be incorporated into the peptidoglycan. To achieve high spatial and temporal resolution, dense, high-intensity fluorescence labeling must be obtained in the shortest possible time. However, modifications carried by d-Ala can hinder their uptake by the enzymes that incorporate them into the peptidoglycan, such as the d,d-transpeptidases. Conversely, these modifications can impede the elimination of the incorporated d-Ala derivatives by d,d-carboxypeptidases, making the labeling more persistent. In this context, we synthesized clickable d-Alas and tested their incorporation into the peptidoglycan using different labeling approaches, prior or after their conjugation to clickable fluorescent dyes through SPAAC reaction. Our data allow ranking of the d-Ala derivatives in terms of their ease of incorporation and resistance to trimming during one-step, "one-pot" two-step or sequential two-step labeling strategies. We further show that a hybrid "one-step" approach, in which a FDA is used in combination with clickable choline and fluorescent dye, enables two-color co-labeling of peptidoglycan and teichoic acids. Finally, we identify a strategy compatible with the cell fixation required for super-resolution microscopy, by combining one-step labeling with FDA and sequential two-step labeling with clickable choline and fluorescent dye, allowing to obtain two-color high-resolution images of peptidoglycan and teichoic acid synthesis regions., Competing Interests: The authors declare no competing interests., (This journal is © The Royal Society of Chemistry.)

Published
2024
Full Text
View/download PDF

338. HMGB1 cleavage by complement C1s and its potent anti-inflammatory product.

Author

Lorvellec M, Chouquet A, Koch J, Bally I, Signor L, Vigne J, Dalonneau F, Thielens NM, Rabilloud T, Dalzon B, Rossi V, and Gaboriaud C

Subjects
Humans, Complement C4 metabolism, Lipopolysaccharides, Anti-Inflammatory Agents, Complement C1s, HMGB1 Protein
Abstract

Complement C1s association with the pathogenesis of several diseases cannot be simply explained only by considering its main role in activating the classical complement pathway. This suggests that non-canonical functions are to be deciphered for this protease. Here the focus is on C1s cleavage of HMGB1 as an auxiliary target. HMGB1 is a chromatin non-histone nuclear protein, which exerts in fact multiple functions depending on its location and its post-translational modifications. In the extracellular compartment, HMGB1 can amplify immune and inflammatory responses to danger associated molecular patterns, in health and disease. Among possible regulatory mechanisms, proteolytic processing could be highly relevant for HMGB1 functional modulation. The unique properties of HMGB1 cleavage by C1s are analyzed in details. For example, C1s cannot cleave the HMGB1 A-box fragment, which has been described in the literature as an inhibitor/antagonist of HMGB1. By mass spectrometry, C1s cleavage was experimentally identified to occur after lysine on position 65, 128 and 172 in HMGB1. Compared to previously identified C1s cleavage sites, the ones identified here are uncommon, and their analysis suggests that local conformational changes are required before cleavage at certain positions. This is in line with the observation that HMGB1 cleavage by C1s is far slower when compared to human neutrophil elastase. Recombinant expression of cleavage fragments and site-directed mutagenesis were used to confirm these results and to explore how the output of C1s cleavage on HMGB1 is finely modulated by the molecular environment. Furthermore, knowing the antagonist effect of the isolated recombinant A-box subdomain in several pathophysiological contexts, we wondered if C1s cleavage could generate natural antagonist fragments. As a functional readout, IL-6 secretion following moderate LPS activation of RAW264.7 macrophage was investigated, using LPS alone or in complex with HMGB1 or some recombinant fragments. This study revealed that a N-terminal fragment released by C1s cleavage bears stronger antagonist properties as compared to the A-box, which was not expected. We discuss how this fragment could provide a potent brake for the inflammatory process, opening the way to dampen inflammation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Lorvellec, Chouquet, Koch, Bally, Signor, Vigne, Dalonneau, Thielens, Rabilloud, Dalzon, Rossi and Gaboriaud.)

Published
2023
Full Text
View/download PDF

339. Biophysical Characterization of the Oligomeric States of Recombinant Immunoglobulins Type-M and Their C1q-Binding Kinetics by Biolayer Interferometry.

Author

Chouquet A, Pinto AJ, Hennicke J, Ling WL, Bally I, Schwaigerlehner L, Thielens NM, Kunert R, and Reiser JB

Abstract

Immunoglobulins type-M (IgMs) are one of the first antibody classes mobilized during immune responses against pathogens and tumor cells. Binding to specific target antigens enables the interaction with the C1 complex which strongly activates the classical complement pathway. This biological function is the basis for the huge therapeutic potential of IgMs. But, due to their high oligomeric complexity, in vitro production, biochemical characterization, and biophysical characterization are challenging. In this study, we present recombinant production of two IgM models (IgM617 and IgM012) in pentameric and hexameric states and the evaluation of their polymer distribution using different biophysical methods (analytical ultracentrifugation, size exclusion chromatography coupled to multi-angle laser light scattering, mass photometry, and transmission electron microscopy). Each IgM construct is defined by a specific expression and purification pattern with different sample quality. Nevertheless, both purified IgMs were able to activate complement in a C1q-dependent manner. More importantly, BioLayer Interferometry (BLI) was used for characterizing the kinetics of C1q binding to recombinant IgMs. We show that recombinant IgMs possess similar C1q-binding properties as IgMs purified from human plasma., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Chouquet, Pinto, Hennicke, Ling, Bally, Schwaigerlehner, Thielens, Kunert and Reiser.)

Published
2022
Full Text
View/download PDF

340. Complement C1q Interacts With LRP1 Clusters II and IV Through a Site Close but Different From the Binding Site of Its C1r and C1s-Associated Proteases.

Author

Fouët G, Gout E, Wicker-Planquart C, Bally I, De Nardis C, Dedieu S, Chouquet A, Gaboriaud C, Thielens NM, Kleman JP, and Rossi V

Subjects
Animals, Apoptosis physiology, Binding Sites physiology, CHO Cells, Cell Line, Cell Membrane metabolism, Cricetulus, HEK293 Cells, Humans, Ligands, Protein Domains physiology, Complement C1q metabolism, Complement C1r metabolism, Complement C1s metabolism, Low Density Lipoprotein Receptor-Related Protein-1 metabolism, Peptide Hydrolases metabolism
Abstract

LRP1 is a large endocytic modular receptor that plays a crucial role in the scavenging of apoptotic material through binding to pattern-recognition molecules. It is a membrane anchored receptor of the LDL receptor family with 4 extracellular clusters of ligand binding modules called cysteine rich complement-type repeats that are involved in the interaction of LRP1 with its numerous ligands. Complement C1q was shown to interact with LRP1 and to be implicated in the phagocytosis of apoptotic cells. The present work aimed at exploring how these two large molecules interact at the molecular level using a dissection strategy. For that purpose, recombinant LRP1 clusters II, III and IV were produced in mammalian HEK293F cells and their binding properties were investigated. Clusters II and IV were found to interact specifically and efficiently with C1q with K Ds in the nanomolar range. The use of truncated C1q fragments and recombinant mutated C1q allowed to localize more precisely the binding site for LRP1 on the collagen-like regions of C1q (CLRs), nearby the site that is implicated in the interaction with the cognate protease tetramer C1r2s2. This site could be a common anchorage for other ligands of C1q CLRs such as sulfated proteoglycans and Complement receptor type 1. The use of a cellular model, consisting in CHO LRP1-null cells transfected with full-length LRP1 or a cluster IV minireceptor (mini IV) confirmed that mini IV interacts with C1q at the cell membrane as well as full-length LRP1. Further cellular interaction studies finally highlighted that mini IV can endorse the full-length LRP1 binding efficiency for apoptotic cells and that C1q has no impact on this interaction., (Copyright © 2020 Fouët, Gout, Wicker-Planquart, Bally, De Nardis, Dedieu, Chouquet, Gaboriaud, Thielens, Kleman and Rossi.)

Published
2020
Full Text
View/download PDF

341. Two Different Missense C1S Mutations, Associated to Periodontal Ehlers-Danlos Syndrome, Lead to Identical Molecular Outcomes.

Author

Bally I, Dalonneau F, Chouquet A, Gröbner R, Amberger A, Kapferer-Seebacher I, Stoiber H, Zschocke J, Thielens NM, Rossi V, and Gaboriaud C

Subjects
Amino Acid Substitution, HEK293 Cells, Humans, Protein Folding, Complement C1r genetics, Complement C1r immunology, Complement C1s genetics, Complement C1s immunology, Ehlers-Danlos Syndrome genetics, Ehlers-Danlos Syndrome immunology, Ehlers-Danlos Syndrome pathology, Mutation, Missense, Periodontal Diseases genetics, Periodontal Diseases immunology, Periodontal Diseases pathology
Abstract

Ehlers-Danlos syndromes (EDS) are clinically and genetically heterogeneous disorders characterized by soft connective tissue alteration like joint hypermobility and skin hyper-extensibility. We previously identified heterozygous missense mutations in the C1R and C1S genes, coding for the complement C1 proteases, in patients affected by periodontal EDS, a specific EDS subtype hallmarked by early severe periodontitis leading to premature loss of teeth and connective tissue alterations. Up to now, there is no clear molecular link relating the nominal role of the C1r and C1s proteases, which is to activate the classical complement pathway, to these heterogeneous symptoms of periodontal EDS syndrome. We aim therefore to elucidate the functional effect of these mutations, at the molecular and enzymatic levels. To explore the molecular consequences, a set of cell transfection experiments, recombinant protein purification, mass spectroscopy and N-terminal analyses have been performed. Focusing on the results obtained on two different C1S variants, namely p.Val316del and p.Cys294Arg, we show that HEK293-F cells stably transfected with the corresponding C1s variant plasmids, unexpectedly, do not secrete the full-length mutated C1s, but only a truncated Fg40 fragment of 40 kDa, produced at very low levels. Detailed analyses of the Fg40 fragments purified for the two C1s variants show that they are identical, which was also unexpected. This suggests that local misfolding of the CCP1 module containing the patient mutation exposes a novel cleavage site, between Lys353 and Cys354, which is not normally accessible. The mutation-induced Fg40 fragment contains the intact C-terminal serine protease domain but not the N-terminal domain mediating C1s interaction with the other C1 subunits, C1r, and C1q. Thus, Fg40 enzymatic activity escapes the normal physiological control of C1s activity within C1, potentially providing a loss-of-control. Comparative enzymatic analyses show that Fg40 retains the native esterolytic activity of C1s, as well as its cleavage efficiency toward the ancillary alarmin HMGB1 substrate, for example, whereas the nominal complement C4 activation cleavage is impaired. These new results open the way to further molecular explorations possibly involving subsidiary C1s targets., (Copyright © 2019 Bally, Dalonneau, Chouquet, Gröbner, Amberger, Kapferer-Seebacher, Stoiber, Zschocke, Thielens, Rossi and Gaboriaud.)

Published
2019
Full Text
View/download PDF

342. Structures of parasite calreticulins provide insights into their flexibility and dual carbohydrate/peptide-binding properties.

Author

Moreau C, Cioci G, Iannello M, Laffly E, Chouquet A, Ferreira A, Thielens NM, and Gaboriaud C

Abstract

Calreticulin (CRT) is a multifaceted protein, initially discovered as an endoplasmic reticulum (ER) chaperone protein, that is essential in calcium metabolism. Various implications in cancer, early development and immunology have been discovered more recently for CRT, as well as its role as a dominant 'eat-me' prophagocytic signal. Intriguingly, cell-surface exposure/secretion of CRT is among the infective strategies used by parasites such as Trypanosoma cruzi , Entamoeba histolytica , Taenia solium , Leishmania donovani and Schistosoma mansoni . Because of the inherent flexibility of CRTs, their analysis by X-ray crystallography requires the design of recombinant constructs suitable for crystallization, and thus only the structures of two very similar mammalian CRT lectin domains are known. With the X-ray structures of two distant parasite CRTs, insights into species structural determinants that might be harnessed to fight against the parasites without affecting the functions of the host CRT are now provided. Moreover, although the hypothesis that CRT can exhibit both open and closed conformations has been proposed in relation to its chaperone function, only the open conformation has so far been observed in crystal structures. The first evidence is now provided of a complex conformational transition with the junction reoriented towards P-domain closure. SAXS experiments also provided additional information about the flexibility of T. cruzi CRT in solution, thus complementing crystallographic data on the open conformation. Finally, regarding the conserved lectin-domain structure and chaperone function, evidence is provided of its dual carbohydrate/protein specificity and a new scheme is proposed to interpret such unusual substrate-binding properties. These fascinating features are fully consistent with previous experimental observations, as discussed considering the broad spectrum of CRT sequence conservations and differences.

Published
2016
Full Text
View/download PDF

343. Structural and Functional Characterization of a Single-Chain Form of the Recognition Domain of Complement Protein C1q.

Author

Moreau C, Bally I, Chouquet A, Bottazzi B, Ghebrehiwet B, Gaboriaud C, and Thielens N

Abstract

Complement C1q is a soluble pattern recognition molecule comprising six heterotrimeric subunits assembled from three polypeptide chains (A-C). Each heterotrimer forms a collagen-like stem prolonged by a globular recognition domain. These recognition domains sense a wide variety of ligands, including pathogens and altered-self components. Ligand recognition is either direct or mediated by immunoglobulins or pentraxins. Multivalent binding of C1q to its targets triggers immune effector mechanisms mediated via its collagen-like stems. The induced immune response includes activation of the classical complement pathway and enhancement of the phagocytosis of the recognized target. We report here, the first production of a single-chain recombinant form of human C1q globular region (C1q-scGR). The three monomers have been linked in tandem to generate a single continuous polypeptide, based on a strategy previously used for adiponectin, a protein structurally related to C1q. The resulting C1q-scGR protein was produced at high yield in stably transfected 293-F mammalian cells. Recombinant C1q-scGR was correctly folded, as demonstrated by its X-ray crystal structure solved at a resolution of 1.35 Å. Its interaction properties were assessed by surface plasmon resonance analysis using the following physiological C1q ligands: the receptor for C1q globular heads, the long pentraxin PTX3, calreticulin, and heparin. The 3D structure and the binding properties of C1q-scGR were similar to those of the three-chain fragment generated by collagenase digestion of serum-derived C1q. Comparison of the interaction properties of the fragments with those of native C1q provided insights into the avidity component associated with the hexameric assembly of C1q. The interest of this functional recombinant form of the recognition domains of C1q in basic research and its potential biomedical applications are discussed.

Published
2016
Full Text
View/download PDF

344. 1H, 13C and 15N resonance assignments of YajG, an Escherichia coli protein of unknown structure and function.

Author

Boudet J, Chouquet A, Chahboune A, Giustini C, Joris B, Simorre JP, and Bougault C

Subjects
Base Sequence, DNA Primers genetics, DNA, Bacterial genetics, Escherichia coli Proteins genetics, Lipoproteins chemistry, Lipoproteins genetics, Molecular Structure, Nuclear Magnetic Resonance, Biomolecular, Recombinant Proteins chemistry, Recombinant Proteins genetics, Escherichia coli Proteins chemistry
Abstract

The ampG gene codes for a permease required to uptake anhydro-muropeptides into bacterial cytoplasm. Located upstream in the same operon, is another 579-base-pair-long open reading frame encoding a putative lipoprotein YajG, whose nearly complete 1H,13C,15N assignments are reported here.

Published
2007
Full Text
View/download PDF

345. [Pre- and postoperative ICGA exploration in neovascular membrane surgery].

Author

Le Quoy O and Chouquet A

Subjects
Adult, Aged, Angiography methods, Humans, Middle Aged, Retrospective Studies, Choroidal Neovascularization diagnostic imaging, Choroidal Neovascularization surgery, Coloring Agents, Indocyanine Green, Postoperative Care, Preoperative Care, Retinal Neovascularization diagnostic imaging, Retinal Neovascularization surgery
Abstract

Introduction: We performed a retrospective analysis of the use of indocyanine green angiography (ICGA) pre- and postoperatively in the surgery of neovascular membranes., Materials and Methods: 81 membranes with retrofovealar extension visible on fluoresceine angiography were operated by vitrectomy and membrane removal from May 1994 to December 1998. Fifty-three had age-related macular degeneration (ARMD), 13 were due to high myopia, and 16 were complications of various inflammatory pathologies. Preoperative evaluation included ICGA, fluoresceine angiography, scanning laser ophthalmoscopy with the study of fixation by microperimetry, and, in recent cases, ocular coherence tomography., Results: ICGA was a definite help in the indication to operate in all cases of ARMD. For 8 cases of inflammatory pathologies, ICGA identified the neovascular membrane within the inflammatory site. ICGA has definite prognostic value in membranes complicating high myopia. Postoperatively, ICGA confirmed the disappearance of neovascularization in ARMD and in the inflammatory group., Conclusions: ICGA is indispensable in the preoperative evaluation of choroidal subretinal neovascular membranes. Postoperatively, ICGA can identify relapses.

Published
2001

346. [Surgery of retrofoveal neovascularization in inflammatory diseases: indications and results. A retrospective study].

Author

Le Quoy O, Chouquet A, and Marchetti R

Subjects
Adolescent, Adult, Child, Choroiditis diagnosis, Choroiditis etiology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Recurrence, Retinal Neovascularization diagnosis, Retinitis diagnosis, Retinitis etiology, Toxoplasmosis, Ocular diagnosis, Visual Acuity, Choroiditis surgery, Postoperative Complications diagnosis, Retinal Neovascularization surgery, Retinitis surgery, Toxoplasmosis, Ocular surgery, Vitrectomy
Published
1999

Catalog

Books, media, physical & digital resources
See catalog results